Section/item	ltem No	Recommendation	Reported on Page Number/Line Number	Reported on Section/Paragraph
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the abstract	Pages 3/ lines 37-40	Abstract/ para2
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	Pages 3-4/ lines 50-52	Abstract/ para3
Introduction				
Background/ rationale	2	Explain the scientific background and rationale for the investigation being reported	Pages 5-6/ lines 63-77	Introduction/ para1-2
Objectives	3	State specific objectives, including any prespecified hypotheses	Page 6/ lines 78-80	Introduction/ para3
Methods				
Study design	4	Present key elements of study design early in the paper	Page 6/ lines 89-91	Methods/ para1
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	Pages 6-8/ lines 86-90, 94- 109, and 127-134	Methods/para1-3
Participants	6	 (a) Cohort study—Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up Case-control study—Give the eligibility criteria, and the sources and methods of case ascertainment and control selection. Give the rationale for the choice of cases and controls Cross-sectional study—Give the eligibility criteria, and the sources and methods of selection of participants 	Page 6/ line 86-89	Methods/para1
		(b) Cohort study —For matched studies, give matching criteria and number of exposed and unexposed Case-control study —For matched studies, give matching criteria and the number of controls per case	Not applicable	Not applicable
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	Pages 6-7/ lines 91-93 Pages 7-8/ lines 111-118	Methods/para 1-2
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	Pages 7-8/ lines 98-106, 120-134	Methods/para1, 3
Bias	9	Describe any efforts to address potential sources of bias	Page 6/ lines 88-89	Method para1
Study size	10	Explain how the study size was arrived at	Page 6/ lines 86-89	Method para1
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	Pages8-9/ lines 136-139	Method para4

STROBE Statement—checklist of items that should be included in reports of observational studies

12	(a) Describe all statistical methods, including those used to control for confounding	Page 9/ lines 137-143	Method para4
	(b) Describe any methods used to examine subgroups and interactions	Not applicable	Not applicable
	(c) Explain how missing data were addressed	Page 7/ lines105-106	Method para1
	(d) Cohort study —If applicable, explain how loss to follow-up was addressed Case-control study —If applicable, explain how matching of cases and controls was addressed Cross-sectional study —If applicable, describe analytical methods taking account of sampling strategy	Not applicable	Not applicable
	(e) Describe any sensitivity analyses	Not applicable	Not applicable
			·
13*	(a) Report numbers of individuals at each stage of study – eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	Page 9/ lines 147-150	Result para1
	(b) Give reasons for non-participation at each stage	Page 9/ lines 148-149	Result para1
	(c) Consider use of a flow diagram	Figure 1	Figure
14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders	Table 1	Table
	(b) Indicate number of participants with missing data for each variable of interest	Table2	Table
	(c) Cohort study —Summarise follow-up time (eg, average and total amount)	Not applicable	Not applicable
15*	Cohort study – Report numbers of outcome events or summary measures over time	Not applicable	Not applicable
	Case-control study – Report numbers in each exposure category, or summary measures of exposure	Page 9/ lines 154-155	Result para 3
	Cross-sectional study – Report numbers of outcome events or summary measures	Not applicable	Not applicable
16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included	Not applicable/ no confounder adjusted	Not applicable
	(b) Report category boundaries when continuous variables were categorized	Table 4	Table
	(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	Not applicable	Not applicable
17	Report other analyses done-eg analyses of subgroups and interactions, and sensitivity analyses	Page 11/ lines 200-204	Result/ para 5
,			
18	Summarise key results with reference to study objectives	Page 14/ lines 286-290	Conclusion
19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction	Page13/ lines 225-243	Discussion/ para2
	13* 14* 15* 16 17 18	(b) Describe any methods used to examine subgroups and interactions (c) Explain how missing data were addressed (d) Cohort study—If applicable, explain how loss to follow-up was addressed Case-control study—If applicable, explain how matching of cases and controls was addressed Cross-sectional study—If applicable, explain how matching of cases and controls was addressed (e) Describe any sensitivity analyses 13* (a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed (b) Give reasons for non-participation at each stage (c) Consider use of a flow diagram 14* (a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders (b) Indicate number of participants with missing data for each variable of interest (c) Cohort study—Summarise follow-up time (eg, average and total armount) 15* Cohort study—Report numbers of outcome events or summary measures over time Case-control study—Report numbers of outcome events or summary measures (a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included (b) Report category boundaries when continuous variables were categorized (c) If relevant, consider translating estimates of relative risk into absol	1 1

Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	Page14-15/ lines 245-269	Discussion/ para3, 4				
Generalisability	21	Discuss the generalisability (external validity) of the study results	Page 15/ line 272-283	Discussion/ para5				
Other information								
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	Not applicable	Not applicable				

*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at http://www.plosmedicine.org/, Annals of Internal Medicine at http://www.annals.org/, and Epidemiology at http://www.epidem.com/). Information on the STROBE Initiative is available at www.strobe-statement.org.

Article information: https://dx.doi.org/10.21037/jtd-23-848

*As the checklist was provided upon initial submission, the page number/line number reported may be changed due to copyediting and may not be referable in the published version. In this case, the section/paragraph may be used as an alternative reference.